This issue features a special section on the implications for practice and policy of the STAR*D findings. Sequenced Treatment Alternatives to Relieve Depression (2000–2004), which sought to determine the most effective next steps for individuals whose symptoms do not remit after an initial antidepressant trial. Key features were its recruitment of a diverse sample of "real-world" patients and its four-level algorithm design, in which clinicians in both specialty and primary care used a measurement-based approach to address treatment-resistant depression. The idea for the special section came from Guest Editor Grayson S. Norquist, M.D., M.S.P.H., a Psychiatric Services editorial board member, who notes in his introduction that another important aim of the NIMH-funded trial was to create an infrastructure that would build capacity and provide a platform for state-of-the-art clinical research (page 1437). The special section begins with an overview of STAR*D and its findings (page 1439) and a review of STAR*D's contributions to pharmacogenetics research—nearly 2,000 participants provided DNA samples (page 1446). The perspectives of four stakeholder groups follow: consumers (page 1458), primary care providers (page 1460), insurers (page 1463), and NIMH (page 1466).